Takeda Pharmaceutical Company (TAK) has released an update.
The U.S. FDA has approved Takeda’s ENTYVIO (vedolizumab) for subcutaneous administration as a maintenance therapy for adults with moderately to severely active Crohn’s Disease, expanding its availability alongside the existing IV option. The approval is backed by the VISIBLE 2 clinical trial, which showed that nearly half of the patients achieved long-term clinical remission. This new form of administration offers patients the flexibility to self-administer their treatment at home or on the move.
For further insights into TAK stock, check out TipRanks’ Stock Analysis page.
